Hori­zon adds 'se­vere hear­ing im­pair­men­t' warn­ing to block­buster's la­bel

The FDA re­cent­ly added a new warn­ing and pre­cau­tion to the la­bel of Hori­zon’s block­buster mon­o­clon­al an­ti­body Te­pez­za (tepro­tu­mum­ab-trbw), which is used as a treat­ment for thy­roid eye dis­ease, to cau­tion pa­tients about the po­ten­tial for se­vere hear­ing-re­lat­ed side ef­fects.

The la­bel for Te­pez­za, an in­sulin-like growth fac­tor-1 re­cep­tor in­hibitor that can re­duce eye bulging and dou­ble vi­sion, now says the drug “may cause se­vere hear­ing im­pair­ment in­clud­ing hear­ing loss, which in some cas­es may be per­ma­nent.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER